^
    17d
    MRG003 Plus Toripalimab Versus Toripalimab as Neoadjuvant Therapy for PD-L1-Positive, Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=65, Not yet recruiting, Dongguan People's Hospital
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Loqtorzi (toripalimab-tpzi) • Meiyouheng (becotatug vedotin)
    21d
    A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3, N=570, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.
    New P3 trial
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • Loqtorzi (toripalimab-tpzi) • Tevimbra (tislelizumab-jsgr) • pemetrexed • Enshuxing (enlonstobart) • SYS6010
    21d
    A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
    New P2 trial
    22d
    BL-B01D1-303: A Phase III clinical trial comparing BL-B01D1 with physician-selected chemotherapy regimens (last line) in patients with recurrent or metastatic nasopharyngeal carcinoma who had previously received PD-1/PD-L1 monoclonal antibody therapy and failed at least two lines of chemotherapy. (clinicaltrials.gov)
    P3, N=386, Active, not recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | -> Active, not recruiting | Phase classification: PN/A --> P3
    Enrollment closed • Phase classification
    |
    PD-L1 (Programmed death ligand 1)
    |
    gemcitabine • docetaxel • capecitabine • izalontamab brengitecan (BL-B01D1)
    23d
    Comprehensive analysis of antibody-drug conjugate (ADC) targets in adenoid cystic carcinoma: examining antigen expression in relation to clinicopathological features, prognosis, and initial therapeutic outcomes. (PubMed, Transl Oncol)
    Importantly, early clinical studies demonstrated that the EGFR-targeted ADC MRG003 and the TROP2-targeted ADC Sac-TMT showed notable efficacy in patients with refractory ACC and high expression of these targets. This pioneering study introduces a biomarker-based stratification system, categorizing ACC patients by histological subtype and target expression profiles, EGFR/TROP2 for non-solid ACC and B7-H4/Nectin-4 for solid ACC, to inform ADC therapy decisions.
    Journal
    |
    AXL (AXL Receptor Tyrosine Kinase) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1) • NECTIN4 (Nectin Cell Adhesion Molecule 4) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    EGFR expression
    |
    Meiyouheng (becotatug vedotin) • Jiataile (sacituzumab tirumotecan)
    23d
    RESERVE-HC: Neoadjuvant EGFR-ADC Combined With Anti-PD-1 Monoclonal Antibody in Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=52, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    1m
    7MeERT Enhances Antibody-Drug Conjugate Efficacy in Glioblastoma by Inducing AMPK-p38MAPK-Mediated Non-Canonical Endocytosis of EGFRvIII. (PubMed, Anticancer Agents Med Chem)
    7MeERT enhances EGFRvIII-targeting ADC efficacy in glioblastoma by inducing metabolic stress and triggering AMPK-p38MAPK-mediated non-canonical endocytosis. This strategy may improve ADC delivery in tumors with impaired receptor internalization.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • AMPK (Protein Kinase AMP-Activated Catalytic Subunit Alpha 1)
    |
    depatuxizumab mafodotin (ABT-414)
    1m
    A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent and Metastatic Cervical Cancer, Vulvar Cancer and Vaginal Cancer (clinicaltrials.gov)
    P2, N=30, Recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Tyvyt (sintilimab) • Yutuo (zimberelimab) • Meiyouheng (becotatug vedotin)
    1m
    Becotatug Vedotin Plus Pucotenlimab for Advanced Biliary Tract Cancer, Phase II (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, HuiKai Li
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    1m
    A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03) (clinicaltrials.gov)
    P3, N=446, Not yet recruiting, Sichuan Baili Pharmaceutical Co., Ltd.
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    capecitabine • albumin-bound paclitaxel • izalontamab brengitecan (BL-B01D1)
    1m
    PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC (clinicaltrials.gov)
    P1, N=396, Not yet recruiting, Hansoh BioMedical R&D Company
    New P1 trial
    |
    Ameile (aumolertinib)
    1m
    A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08) (clinicaltrials.gov)
    P3, N=418, Not yet recruiting, Sichuan Baili Pharmaceutical Co., Ltd.
    New P3 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • izalontamab brengitecan (BL-B01D1)